Literature DB >> 24029204

Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.

V N R Das1, K Pandey, D Singh, C Forwood, C S Lal, P Das.   

Abstract

We report two cases, one male (33 years) and a female (14 years), that developed Post-Kala-azar Dermal Leishmaniasis (PKDL) after successful treatment for visceral leishmaniasis (VL) or Kala-azar with AmBisome, the lipid complex of Amphotericin B. Both cases presented with hypo-pigmented macular lesions all over the body. The patients responded well to AmBisome after treatment with three courses. This first ever case report from India indicates that possibly there is no effective drug for VL until date, which can prevent post-treatment development of PKDL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24029204     DOI: 10.4103/0022-3859.118046

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  4 in total

Review 1.  The immunology of post-kala-azar dermal leishmaniasis (PKDL).

Authors:  Eduard E Zijlstra
Journal:  Parasit Vectors       Date:  2016-08-23       Impact factor: 3.876

2.  Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.

Authors:  Semra Palić; Patrick Bhairosing; Jos H Beijnen; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

3.  Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.

Authors:  Dinesh Mondal; Amresh Kumar; Abhijit Sharma; Moshtaq Mural Ahmed; Md Golam Hasnain; Abdul Alim; M Mamun Huda; Ridwanur Rahman; Jorge Alvar; Be-Nazir Ahmed; Rashidul Haque
Journal:  PLoS Negl Trop Dis       Date:  2019-08-15

4.  Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (FungisomeTM) and Short-Course Miltefosine in Comparison to Miltefosine Monotherapy.

Authors:  Rama Prosad Goswami; Mehebubar Rahman; Sukhen Das; Santanu Kumar Tripathi; Rudra Prosad Goswami
Journal:  Am J Trop Med Hyg       Date:  2020-05-07       Impact factor: 2.345

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.